FDA Benzocaine Safety Alert Also Targets Pain From Public Citizen Complaint
Executive Summary
FDA is considering forcing off the market OTC benzocaine oral care products for treating infant teething pain, seven years after acknowledging the ingredient's link to a rare but potentially fatal condition, methemoglobinemia, and raising the possibility of requiring label changes.
You may also be interested in...
Church & Dwight Has International ‘Bright Spot’ In Q2, 'Huge Opportunities' For WaterPik
Firm's consumer products international business showed 6.9% organic growth to $176.1m on higher volume in personal care brands as investments in its export business pay off, says CEO Matthew Farrell. It expects further upside in its non-US business with opportunities to grow the WaterPik power toothbrush brand.
FDA Denies Petition To Pull Teething From OTC Benzocaine Label, Expects Voluntary Changes By Marketers
FDA denies Public Citizen's petition for rulemaking to remove infant teething as an indication for OTC benzocaine and require a contraindication on labels advising against using gel and liquid products for teething pain. The agency has asked marketers for voluntary label changes and says a rulemaking would be too lengthy, but Public Citizen says a rulemaking started when the problem became known would already be completed.
FDA Denies Petition To Pull Teething From OTC Benzocaine Label, Expects Voluntary Changes By Marketers
FDA denies Public Citizen's petition for rulemaking to remove infant teething as an indication for OTC benzocaine and require a contraindication on labels advising against using gel and liquid products for teething pain. The agency has asked marketers for voluntary label changes and says a rulemaking would be too lengthy, but Public Citizen says a rulemaking started when the problem became known would already be completed.